Synthetic Biologics, Inc. (SYN)
Chart Events
Performance Outlook
| Previous Close | 0.4970 |
| Open | 0.4800 |
| Bid | 0.5428 x 800 |
| Ask | 0.5455 x 3100 |
| Day's Range | 0.4700 - 0.5500 |
| 52 Week Range | 0.2500 - 1.7000 |
| Volume | 2,544,043 |
| Avg. Volume | 17,679,276 |
| Market Cap | 70.208M |
| Beta (5Y Monthly) | 1.93 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.6600 |
| Earnings Date | Mar 04, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 1.88 |
- PR Newswire
Synthetic Biologics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients
Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, today announced enrollment has commenced and the first patient has been dosed in its Phase 1b/2a clinical trial of SYN-004 (ribaxamase) in allogeneic hematopoietic cell transplant (HCT) recipients for the prevention of acute graft-versus-host-disease (aGVHD). Broad spectrum intravenous (IV) beta-lactam antibiotics used to treat infection following conditioning chemotherapy for allogeneic HCT patients is a necessary and oftentimes lifesaving intervention. However, antibiotic-mediated damage of the gut microbiome in this patient population has been strongly associated with adverse outcomes including C. difficile infection (CDI), vancomycin-resistant enterococci (VRE) colonization, potentially fatal bacteremia, and aGVHD.
- PR Newswire
Synthetic Biologics Announces First Six Participants Dosed in Phase 1a Clinical Trial of SYN-020 Intestinal Alkaline Phosphatase
Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, today announced that enrollment has commenced and six study participants were dosed in a Phase 1a single-ascending dose clinical trial of SYN-020 intestinal alkaline phosphatase ("IAP").
- PR Newswire
Synthetic Biologics Reports 2020 Year End Operational Highlights and Financial Results
Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, today provided a clinical programs update and reported financial results for the year ended December 31, 2020.
